Targeting LRRK2 in PD represented a decrease in pathological signs of progression such as a reduction in cytokine levels in the brain protecting neurons from neurodegeneration induced by α-synuclein accumulation [5]. The gene discussed is LRRK2; the disease is Parkinson disease.